Latest Product Launches News

ReNerve Limited has entered a strategic partnership with Berkeley Biologics to develop and commercialise two new tissue-based product ranges, aiming to expand its footprint in the US surgical market by the end of 2025.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

Aspermont Limited reports steady subscription growth with $11.2 million in annual recurring revenue despite a dip in total revenue, while gearing up for new data product launches and an IPO.

ikeGPS Group Limited reported a robust 48% growth in annual subscription revenue exit run rate for FY25, alongside improved margins and a narrowed EBITDA loss. Despite a lucrative NZ$1 per share acquisition approach, the company declined the offer, confident in its growth trajectory.

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Straker Ltd has reported a record adjusted EBITDA of NZ$4.8 million for FY25, driven by strong growth in AI subscription services and operational efficiencies, even as overall revenue declined 10.3%. The company’s strategic pivot towards AI-powered offerings signals a promising shift in its business model.

Yowie Group has posted its first profitable seasonal quarter, driven by strategic cost control and product improvements, but faces ongoing capital challenges due to a significant loan default by Keybridge Capital.

The Calmer Co. International Limited has significantly expanded the distribution of its flagship kava products in Coles supermarkets, reflecting growing consumer appetite for natural relaxation alternatives to alcohol.

Australian Vintage outlines a strategic turnaround with innovative product launches and a key acquisition, aiming to reverse declining sales and improve cash flow in FY2026.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Catapult Group International Ltd reported a milestone FY25 with ACV exceeding US$100 million, driven by strong SaaS growth and record profitability. The company’s innovative product launches and improved cost efficiencies underpin a confident outlook for FY26.

Merino & Co has amended its quarterly report to correct expenditure figures and clarify related party payments, while reporting significant operational progress including new product launches and cryptocurrency integration.